REGULATORY
PMDA to Adopt General-Purpose AI in FY2025, Eyes Specialized Tools for Reviews and Safety Work
Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) plans to introduce general-purpose AI during FY2025 to streamline administrative tasks such as drafting meeting minutes, while also exploring the longer-term use of more specialized AI for regulatory work. PMDA Senior Executive Director…
To read the full story
Related Article
- PMDA Lays Out AI Action Plan, Eyes Specialized In-House System
October 14, 2025
REGULATORY
- Officer Replacement Orders a “Last Resort” under PMD Act: MHLW Official
September 18, 2026
- Japan Panel Sees No Scientific Objection to Capvaxive NIP Addition
September 18, 2026
- Tavneos Blue Letter Action “Too Slow,” MHLW Panel Member Says
September 18, 2026
- Takaichi Tasks Ueno with Charting Growth Strategy for Drug Innovation
September 18, 2026
- Japan HIV, AIDS Cases Rise in H1 after 2025 Lows
September 18, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…





